Engineering insulin-like growth factor-1 for local delivery

Tomotake Tokunou, Rachel Miller, Parth Patwari, Michael E. Davis, Vincent F.M. Segers, Alan J. Grodzinsky, Richard T. Lee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Insulin-like growth factor-1 (IGF-1) is a small protein that promotes cell survival and growth, often acting over long distances. Although for decades IGF-1 has been considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and local delivery of IGF-1 for tissue repair has been a long-standing challenge. In this study, we designed and purified a novel protein, heparin-binding IGF-1 (Xp-HB-IGF-1), which is a fusion protein of native IGF-1 with the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor. Xp-HB-IGF-1 bound selectively to heparin as well as the cell surfaces of 3T3 fibroblasts, neonatal cardiac myocytes and differentiating ES cells. Xp-HB-IGF-1 activated the IGF-1 receptor and Akt with identical kinetics and dose response, indicating no compromise of biological activity due to the heparin-binding domain. Because cartilage is a proteoglycan-rich environment and IGF-1 is a known stimulus for chondrocyte biosynthesis, we then studied the effectiveness of Xp-HB-IGF-1 in cartilage. Xp-HB-IGF-1 was selectively retained by cartilage explants and led to sustained chondrocyte proteoglycan biosynthesis compared to IGF-1. These data show that the strategy of engineering a "long-distance" growth factor like IGF-1 for local delivery may be useful for tissue repair and minimizing systemic effects.

Original languageEnglish
Pages (from-to)1886-1893
Number of pages8
JournalFASEB Journal
Volume22
Issue number6
DOIs
Publication statusPublished - Jun 1 2008
Externally publishedYes

Fingerprint

somatomedins
Somatomedins
engineering
heparin
Heparin
Cartilage
cartilage
proteoglycans
Proteoglycans
chondrocytes
Chondrocytes
Biosynthesis
tissue repair
growth factors
Intercellular Signaling Peptides and Proteins
Repair
biosynthesis
Somatomedin Receptors
Insulin-Like Growth Factor Binding Protein 1
3T3 Cells

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Tokunou, T., Miller, R., Patwari, P., Davis, M. E., Segers, V. F. M., Grodzinsky, A. J., & Lee, R. T. (2008). Engineering insulin-like growth factor-1 for local delivery. FASEB Journal, 22(6), 1886-1893. https://doi.org/10.1096/fj.07-100925

Engineering insulin-like growth factor-1 for local delivery. / Tokunou, Tomotake; Miller, Rachel; Patwari, Parth; Davis, Michael E.; Segers, Vincent F.M.; Grodzinsky, Alan J.; Lee, Richard T.

In: FASEB Journal, Vol. 22, No. 6, 01.06.2008, p. 1886-1893.

Research output: Contribution to journalArticle

Tokunou, T, Miller, R, Patwari, P, Davis, ME, Segers, VFM, Grodzinsky, AJ & Lee, RT 2008, 'Engineering insulin-like growth factor-1 for local delivery', FASEB Journal, vol. 22, no. 6, pp. 1886-1893. https://doi.org/10.1096/fj.07-100925
Tokunou T, Miller R, Patwari P, Davis ME, Segers VFM, Grodzinsky AJ et al. Engineering insulin-like growth factor-1 for local delivery. FASEB Journal. 2008 Jun 1;22(6):1886-1893. https://doi.org/10.1096/fj.07-100925
Tokunou, Tomotake ; Miller, Rachel ; Patwari, Parth ; Davis, Michael E. ; Segers, Vincent F.M. ; Grodzinsky, Alan J. ; Lee, Richard T. / Engineering insulin-like growth factor-1 for local delivery. In: FASEB Journal. 2008 ; Vol. 22, No. 6. pp. 1886-1893.
@article{9c0b64c73aa7434c9f3cd14abdb04f1e,
title = "Engineering insulin-like growth factor-1 for local delivery",
abstract = "Insulin-like growth factor-1 (IGF-1) is a small protein that promotes cell survival and growth, often acting over long distances. Although for decades IGF-1 has been considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and local delivery of IGF-1 for tissue repair has been a long-standing challenge. In this study, we designed and purified a novel protein, heparin-binding IGF-1 (Xp-HB-IGF-1), which is a fusion protein of native IGF-1 with the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor. Xp-HB-IGF-1 bound selectively to heparin as well as the cell surfaces of 3T3 fibroblasts, neonatal cardiac myocytes and differentiating ES cells. Xp-HB-IGF-1 activated the IGF-1 receptor and Akt with identical kinetics and dose response, indicating no compromise of biological activity due to the heparin-binding domain. Because cartilage is a proteoglycan-rich environment and IGF-1 is a known stimulus for chondrocyte biosynthesis, we then studied the effectiveness of Xp-HB-IGF-1 in cartilage. Xp-HB-IGF-1 was selectively retained by cartilage explants and led to sustained chondrocyte proteoglycan biosynthesis compared to IGF-1. These data show that the strategy of engineering a {"}long-distance{"} growth factor like IGF-1 for local delivery may be useful for tissue repair and minimizing systemic effects.",
author = "Tomotake Tokunou and Rachel Miller and Parth Patwari and Davis, {Michael E.} and Segers, {Vincent F.M.} and Grodzinsky, {Alan J.} and Lee, {Richard T.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1096/fj.07-100925",
language = "English",
volume = "22",
pages = "1886--1893",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Engineering insulin-like growth factor-1 for local delivery

AU - Tokunou, Tomotake

AU - Miller, Rachel

AU - Patwari, Parth

AU - Davis, Michael E.

AU - Segers, Vincent F.M.

AU - Grodzinsky, Alan J.

AU - Lee, Richard T.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Insulin-like growth factor-1 (IGF-1) is a small protein that promotes cell survival and growth, often acting over long distances. Although for decades IGF-1 has been considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and local delivery of IGF-1 for tissue repair has been a long-standing challenge. In this study, we designed and purified a novel protein, heparin-binding IGF-1 (Xp-HB-IGF-1), which is a fusion protein of native IGF-1 with the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor. Xp-HB-IGF-1 bound selectively to heparin as well as the cell surfaces of 3T3 fibroblasts, neonatal cardiac myocytes and differentiating ES cells. Xp-HB-IGF-1 activated the IGF-1 receptor and Akt with identical kinetics and dose response, indicating no compromise of biological activity due to the heparin-binding domain. Because cartilage is a proteoglycan-rich environment and IGF-1 is a known stimulus for chondrocyte biosynthesis, we then studied the effectiveness of Xp-HB-IGF-1 in cartilage. Xp-HB-IGF-1 was selectively retained by cartilage explants and led to sustained chondrocyte proteoglycan biosynthesis compared to IGF-1. These data show that the strategy of engineering a "long-distance" growth factor like IGF-1 for local delivery may be useful for tissue repair and minimizing systemic effects.

AB - Insulin-like growth factor-1 (IGF-1) is a small protein that promotes cell survival and growth, often acting over long distances. Although for decades IGF-1 has been considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and local delivery of IGF-1 for tissue repair has been a long-standing challenge. In this study, we designed and purified a novel protein, heparin-binding IGF-1 (Xp-HB-IGF-1), which is a fusion protein of native IGF-1 with the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor. Xp-HB-IGF-1 bound selectively to heparin as well as the cell surfaces of 3T3 fibroblasts, neonatal cardiac myocytes and differentiating ES cells. Xp-HB-IGF-1 activated the IGF-1 receptor and Akt with identical kinetics and dose response, indicating no compromise of biological activity due to the heparin-binding domain. Because cartilage is a proteoglycan-rich environment and IGF-1 is a known stimulus for chondrocyte biosynthesis, we then studied the effectiveness of Xp-HB-IGF-1 in cartilage. Xp-HB-IGF-1 was selectively retained by cartilage explants and led to sustained chondrocyte proteoglycan biosynthesis compared to IGF-1. These data show that the strategy of engineering a "long-distance" growth factor like IGF-1 for local delivery may be useful for tissue repair and minimizing systemic effects.

UR - http://www.scopus.com/inward/record.url?scp=44949233726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949233726&partnerID=8YFLogxK

U2 - 10.1096/fj.07-100925

DO - 10.1096/fj.07-100925

M3 - Article

C2 - 18285400

AN - SCOPUS:44949233726

VL - 22

SP - 1886

EP - 1893

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -